According to the report, the Size of the Europe Intraosseous Infusion Devices Market is valued at USD 1.11 Billion in 2023 and is projected to grow at a CAGR of 6.1% to reach USD 1.50 billion by 2028 during the forecast period 2023 to 2028.
The growing senior population has resulted in a larger patient pool and a higher prevalence of various diseases. The increasing quantity of R&D activities and the ever-increasing acceptance of technologically advanced products will help the region expand. Intraosseous infusion is an essential part of osteoarthritis treatment. A technique of platelet-rich plasma (PRP) infiltration for treating severe hip osteoarthritis has been researched for the past few years. In the years ahead, increased demand for critical and emergency operations and an increased incidence of admission to essential and emergency units will likely benefit the European intraosseous infusion devices market.
Furthermore, the medical device industry's growing concern for air medical emergency services and military medics is projected to open up potential intraosseous infusion devices market opportunities throughout the assessment period. Pyng Medical's FAST1 Intraosseous infusion technology is widely used in military medical care facilities in personal combat and army emergencies. The intraosseous infusion devices market is estimated to rise in the next few years due to the incidence of cardiovascular diseases and the number of traumatic surgeries performed in various hospital settings.
The growing demand for automated IO devices is projected to present considerable potential for market participants. Patients under the age of six are deemed safe for automated IO. Automated intraocular access could be particularly useful in emergencies where obtaining peripheral venous access is difficult and time is of the essence. Therefore, the intraosseous infusion devices market is expected to develop throughout the forecast period, owing to an increase in emergency cases and a more critical requirement for rapid vascular access.
An increased risk of compartment syndrome due to the leaking of fluids and drugs into soft tissues and restrictions on use in patients with severe osteoporosis and hypovolemic conditions are some of the factors that could hinder market expansion. In addition, the accessibility of several alternative infusion methods is also a significant factor impeding the growth of the European intraosseous infusion devices market.
This research report on the Europe Intraosseous Infusion Devices Market has been segmented and sub-segmented into the following categories
By Product Type:
By Technology:
By End User:
By Route of Administration:
By Country:
Geographically, the Russia Intraosseous Infusion Devices Market is estimated to account largest of the market. The growing need for intraosseous infusion devices in Russia is primarily due to an aging population, an increase in chronic disease cases, and the presence of well-established clinics that provide high-quality care.
Furthermore, favorable regulatory circumstances are projected to present the intraosseous infusion device with exciting potential in Russia. Trauma and emergencies are the leading causes of cardiovascular disease and death. Most of the time, people in such situations don't have much time and require prompt treatment. Intraosseous Infusion is the most successful and adaptable treatment option. These emergency instances have driven the intraosseous infusion device market despite the deaths. These devices are often utilized when veins have no access to provide essential infusions.
KEY MARKET PLAYERS
Prominent Companies leading the Europe Intraosseous Infusion Devices Market Profiled in the Report are PerSys Medical, Aero Healthcare, Teleflex,Pyng Medical Corp., Biopsybell, Cook Medical Incorporated, Aero Healthcare etc.,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region